Ruxoprubart

NovelMed's Ruxoprubart demonstrated significant efficacy in a Phase II trial for treatment-naïve PNH patients, meeting all primary endpoints including complete transfusion avoidance and increased hemoglobin levels.

December 2024 marked a significant month in nephrology with FDA updates on IgA nephropathy and chronic kidney disease treatments, a new episode of the Kidney Compass podcast focusing on FSGS drug development, and new research highlighting the risks associated with IgAN and FSGS. The FDA cleared a Phase 2 trial for Ruxoprubart in IgAN but issued a CRL for Sotagliflozin in type 1 diabetes and CKD. Research also indicated that IgAN and FSGS patients face a higher risk of requiring kidney replacement therapy.

NovelMed's Ruxoprubart, a selective alternative complement pathway inhibitor, has received FDA IND clearance for a Phase II efficacy trial in Immunoglobulin A Nephropathy (IgAN).

The complement inhibitors market is experiencing growth due to increased understanding of the complement system's role in rare and chronic diseases.